# Biomea Fusion

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biomea-fusion

- Industry: Biotechnology
- Headquarters: Redwood City, US
- Website: www.biomeafusion.com
- Total disclosed funding: $56M
- Latest round: Series A (Dec 23, 2020)
- Investors on record: 9

## About

Biomea Fusion, Inc., based in the US, is a biotechnology firm focused on the discovery and development of innovative oral covalent small molecules to enhance treatment options for patients suffering from diabetes and obesity.Founded in 2017 and headquartered in Redwood City, US, Biomea Fusion, Inc. specializes in developing therapies for chronic metabolic diseases. The company has raised a total of USD 150.00 mn, with its most recent funding round being a Private Placement of USD 150.00 mn on March 2023. The CEO, Thomas Butler, leads the firm which has completed three deals as of April 2021.Biomea Fusion focuses on the discovery and development of oral covalent small molecules aimed at improving the lives of patients with diabetes and obesity. Their core product offerings leverage the proprietary FUSION™ System, designed to create next-generation covalent-binding medicines. These therapies work by forming permanent bonds with target proteins, providing enhanced target selectivity and the potential for more durable therapeutic responses compared to conventional non-covalent drugs. The company is developing a pipeline of three novel covalent inhibitor programs currently in preclinical and clinical development. Their target markets primarily include North America and Europe, addressing the needs of healthcare providers and patients affected by chronic metabolic diseases.Biomea Fusion generates revenue through partnerships and collaborations associated with the development and commercialization of its therapeutic candidates. These transactions typically involve agreements with pharmaceutical companies, healthcare institutions, and research organizations, which may include milestone payments and royalties based on product performance. While specific pricing details for their products and services are not disclosed, their revenue structure aligns with their mission to provide effective treatments for patients with complex health conditions.In April 2021, Biomea Fusion, Inc. raised USD 153.00 mn in an IPO, selling 9 million shares at USD 17 per share on the Nasdaq Global Select Market. The funding will be utilized to advance their first irreversible menin inhibitor into the clinic, further develop two additional irreversible preclinical programs, and expand their research team. The company plans to explore new markets for its innovative therapies, with a focus on expanding its presence in North America and Europe by 2024.

## Funding rounds

- Series A, Dec 23, 2020, $56M — Aisling Capital, RTW Investments, Rock Springs Capital, Cormorant Asset Management, Boxer Capital, Point Sur Investors, Janus Henderson Investors, Logos Capital, Clifton Capital

## Investors

- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series A
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series A
- Rock Springs Capital — Series A
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series A
- Point Sur Investors — Series A
- Janus Henderson Investors — Series A
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series A
- Clifton Capital — Series A